メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
河合 秀樹
循環器内科学
h-index
3174
被引用数
16
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2006
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(56)
類似のプロファイル
(6)
フィンガープリント
Hideki Kawaiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Coronary Computed Tomography Angiography
100%
Computed Tomography Angiography
90%
Computer Assisted Tomography
73%
Revascularization
53%
Acute Decompensated Heart Failure
51%
Intravascular Ultrasound
47%
Coronary Artery
43%
Coronary Artery Obstruction
37%
Chronic Kidney Disease
36%
Heart Failure with Preserved Ejection Fraction
35%
Heart Failure
34%
Cardiac Sarcoidosis
33%
Fractional Flow Reserve
33%
Optical Coherence Tomography
33%
D-Dimer
33%
Carotid Artery
33%
Intensive Care Unit
33%
Stenosis
30%
Coronary Artery Disease
29%
Acute Coronary Syndrome
29%
Ejection Fraction
27%
Coronary Angiography
25%
Heart Left Ventricle Ejection Fraction
22%
Echocardiography
21%
Two Dimensional Speckle Tracking Echocardiography
19%
Fluorodeoxyglucose
19%
Statin
19%
Myocardial Infarction
19%
Thromboembolism
19%
Adverse Outcome
19%
Creatinine
19%
Cardiovascular System
19%
Omega-3 Fatty Acid
18%
Multimodality Imaging
17%
Carotid Artery Stenting
16%
Heat Shock Protein 72
16%
Plaque Characterization
16%
Carotid Endarterectomy
16%
COVID-19
16%
near Infrared Spectroscopy
16%
ST Elevation
16%
Catheterization
16%
Amino Terminal Sequence
16%
Brain Natriuretic Peptide
16%
Heart Muscle Injury
16%
Stomach Cancer
16%
Coil Migration
16%
Coronary Sinus
16%
Acute Kidney Injury
16%
Lancovutide
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
45%
Acute Coronary Syndrome
39%
Statin (Protein)
35%
Heart Failure with Preserved Ejection Fraction
35%
Brain Natriuretic Peptide
33%
Acute Kidney Failure
33%
Lancovutide
33%
Rivaroxaban
33%
Heart Failure
31%
Pitavastatin
26%
Cardiovascular Disease
26%
Disease
22%
Creatinine
21%
Adverse Outcome
21%
Chronic Kidney Failure
20%
Cause of Death
17%
Coronary Artery Disease
16%
Heat Shock Protein 72
16%
Membrane Phospholipid
16%
Acetylsalicylic Acid
16%
Atherosclerosis
16%
Antithrombotic Therapy
16%
C Reactive Protein
16%
Prevalence
16%
Cardiovascular Risk
16%
Troponin T
16%
Icosapentaenoic Acid
16%
Coronavirinae
16%
Rapamycin
16%
Hemodialysis
16%
D Dimer
16%
Spinocerebellar Degeneration
16%
Heart Failure with Reduced Ejection Fraction
16%
Low Density Lipoprotein Cholesterol
16%
Fatty Acid Binding Protein
16%
Omega-3 Fatty Acid
16%
Warfarin
13%
Antiplatelet
13%
Biological Marker
12%
All Cause Mortality
11%
Upacicalcet
11%
Heart Left Ventricle Failure
8%
Survival Rate
7%
Major Adverse Cardiac Event
7%
Docosahexaenoic Acid
6%
Pandemic
6%
Kidney Disease
6%
Lipocortin 5
5%
End Stage Renal Disease
5%
Patient History of Coronary Angioplasty
5%
Keyphrases
Coronary Computed Tomography Angiography
36%
Cardiac Intensive Care Unit
33%
Carotid Revascularization
33%
Acute Coronary Syndrome
22%
Computed Tomography Angiography
22%
Sirolimus-eluting Stent
16%
Acute Kidney Injury
16%
Mild Chronic Kidney Disease
16%
Fatty
16%
Syndrome-based
16%
Primary Stenting
16%
Coronary Plaque Characteristics
16%
Antithrombotic Therapy
16%
Eicosapentaenoic Acid to Arachidonic Acid Ratio
16%
Multimarker Approach
16%
Future Hospital
16%
High-sensitivity Troponin I
16%
Injury Associations
16%
Bleeding Complications
16%
Coronary Artery Stenosis
16%
Major Bleeding
16%
Coronary Artery Stenting
16%
PET Analysis
16%
Echocardiographic Parameters
16%
Renal Angina Index
16%
Non-target Organisms
16%
Isolated Cardiac Sarcoidosis
16%
Duramycin
16%
Radiation Burden
16%
Coronary Sinus
16%
Portal-systemic Collaterals
16%
Coil Migration
16%
Percutaneous Transhepatic Obliteration
16%
Significant Coronary Artery Disease
16%
Urinary Liver-type Fatty Acid Binding Protein
16%
FFRCT
16%
Stable Cardiovascular Disease
16%
Phospholipid Asymmetry
16%
Eicosapentaenoic Acid
16%
On-site Assessment
16%
Angiography-derived Fractional Flow Reserve
16%
Invasive Fractional Flow Reserve
16%
Mid-term Follow-up
16%
Rivaroxaban
16%
Clinical Outcomes
16%
Myocardial Mass
16%
Grayscale
16%
Angiographic Characteristics
16%
Stable Coronary Artery Disease
16%
Coronary Artery Bypass Grafting
16%
